Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo

Yi Chen, Edwin A. Alvarez, Diana Azzam, Seth A. Wander, Natalia Guggisberg, Mercè Jordà, Zhenlin Ju, Bryan T. Hennessy, Joyce M. Slingerland

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Antiestrogen therapies arrest susceptible estrogen receptor (ER)-positive breast cancers by increasing p27. Since Src phosphorylates p27 to promote p27 proteolysis, Src activation observed in up to 40% of ER-positive cancers may contribute to antiestrogen resistance. In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27. Saracatinib and fulvestrant together more effectively increased p27, reduced Ki67, and impaired MDA-MB-361 xenograft tumor growth in vivo than either of the drugs alone. In contrast, saracatinib monotherapy rapidly gave rise to drug resistance. Since combined ER and Src inhibition delays development of resistance in vivo, these data support further clinical investigation of saracatinib in combination with fulvestrant for women with ER-positive breast cancer. Proteomic analysis revealed striking bypass activation of the mTOR pathway in saracatinib-resistant tumors. mTORC1 activation also arose following long-term culture of ER-positive breast cancer lines in the presence of saracatinib. These data indicate the utility of proteomic analysis of drug-resistant tumors to identify potential means of drug resistance. The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.

Original languageEnglish (US)
Pages (from-to)69-78
Number of pages10
JournalBreast Cancer Research and Treatment
Volume128
Issue number1
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Drug Resistance
Estrogen Receptor Modulators
Proteomics
Neoplasms
Pharmaceutical Preparations
saracatinib
In Vitro Techniques
Cell Cycle Checkpoints
Heterografts
Proteolysis
Phosphotransferases
Therapeutics
Growth

Keywords

  • Breast cancer
  • Cell cycle
  • Fulvestrant
  • p27
  • Src inhibitor
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chen, Y., Alvarez, E. A., Azzam, D., Wander, S. A., Guggisberg, N., Jordà, M., ... Slingerland, J. M. (2011). Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Research and Treatment, 128(1), 69-78. https://doi.org/10.1007/s10549-010-1024-7

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. / Chen, Yi; Alvarez, Edwin A.; Azzam, Diana; Wander, Seth A.; Guggisberg, Natalia; Jordà, Mercè; Ju, Zhenlin; Hennessy, Bryan T.; Slingerland, Joyce M.

In: Breast Cancer Research and Treatment, Vol. 128, No. 1, 07.2011, p. 69-78.

Research output: Contribution to journalArticle

Chen, Y, Alvarez, EA, Azzam, D, Wander, SA, Guggisberg, N, Jordà, M, Ju, Z, Hennessy, BT & Slingerland, JM 2011, 'Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo', Breast Cancer Research and Treatment, vol. 128, no. 1, pp. 69-78. https://doi.org/10.1007/s10549-010-1024-7
Chen, Yi ; Alvarez, Edwin A. ; Azzam, Diana ; Wander, Seth A. ; Guggisberg, Natalia ; Jordà, Mercè ; Ju, Zhenlin ; Hennessy, Bryan T. ; Slingerland, Joyce M. / Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. In: Breast Cancer Research and Treatment. 2011 ; Vol. 128, No. 1. pp. 69-78.
@article{7ccf9bf709894468ad5ed17f573c3686,
title = "Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo",
abstract = "Antiestrogen therapies arrest susceptible estrogen receptor (ER)-positive breast cancers by increasing p27. Since Src phosphorylates p27 to promote p27 proteolysis, Src activation observed in up to 40{\%} of ER-positive cancers may contribute to antiestrogen resistance. In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27. Saracatinib and fulvestrant together more effectively increased p27, reduced Ki67, and impaired MDA-MB-361 xenograft tumor growth in vivo than either of the drugs alone. In contrast, saracatinib monotherapy rapidly gave rise to drug resistance. Since combined ER and Src inhibition delays development of resistance in vivo, these data support further clinical investigation of saracatinib in combination with fulvestrant for women with ER-positive breast cancer. Proteomic analysis revealed striking bypass activation of the mTOR pathway in saracatinib-resistant tumors. mTORC1 activation also arose following long-term culture of ER-positive breast cancer lines in the presence of saracatinib. These data indicate the utility of proteomic analysis of drug-resistant tumors to identify potential means of drug resistance. The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.",
keywords = "Breast cancer, Cell cycle, Fulvestrant, p27, Src inhibitor, Tamoxifen",
author = "Yi Chen and Alvarez, {Edwin A.} and Diana Azzam and Wander, {Seth A.} and Natalia Guggisberg and Merc{\`e} Jord{\`a} and Zhenlin Ju and Hennessy, {Bryan T.} and Slingerland, {Joyce M.}",
year = "2011",
month = "7",
doi = "10.1007/s10549-010-1024-7",
language = "English (US)",
volume = "128",
pages = "69--78",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo

AU - Chen, Yi

AU - Alvarez, Edwin A.

AU - Azzam, Diana

AU - Wander, Seth A.

AU - Guggisberg, Natalia

AU - Jordà, Mercè

AU - Ju, Zhenlin

AU - Hennessy, Bryan T.

AU - Slingerland, Joyce M.

PY - 2011/7

Y1 - 2011/7

N2 - Antiestrogen therapies arrest susceptible estrogen receptor (ER)-positive breast cancers by increasing p27. Since Src phosphorylates p27 to promote p27 proteolysis, Src activation observed in up to 40% of ER-positive cancers may contribute to antiestrogen resistance. In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27. Saracatinib and fulvestrant together more effectively increased p27, reduced Ki67, and impaired MDA-MB-361 xenograft tumor growth in vivo than either of the drugs alone. In contrast, saracatinib monotherapy rapidly gave rise to drug resistance. Since combined ER and Src inhibition delays development of resistance in vivo, these data support further clinical investigation of saracatinib in combination with fulvestrant for women with ER-positive breast cancer. Proteomic analysis revealed striking bypass activation of the mTOR pathway in saracatinib-resistant tumors. mTORC1 activation also arose following long-term culture of ER-positive breast cancer lines in the presence of saracatinib. These data indicate the utility of proteomic analysis of drug-resistant tumors to identify potential means of drug resistance. The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.

AB - Antiestrogen therapies arrest susceptible estrogen receptor (ER)-positive breast cancers by increasing p27. Since Src phosphorylates p27 to promote p27 proteolysis, Src activation observed in up to 40% of ER-positive cancers may contribute to antiestrogen resistance. In this article, we show that treatment with the Src-inhibitor saracatinib (AZD0530) together with ER-blocking drugs increased breast cancer cell cycle arrest via p27. Saracatinib and fulvestrant together more effectively increased p27, reduced Ki67, and impaired MDA-MB-361 xenograft tumor growth in vivo than either of the drugs alone. In contrast, saracatinib monotherapy rapidly gave rise to drug resistance. Since combined ER and Src inhibition delays development of resistance in vivo, these data support further clinical investigation of saracatinib in combination with fulvestrant for women with ER-positive breast cancer. Proteomic analysis revealed striking bypass activation of the mTOR pathway in saracatinib-resistant tumors. mTORC1 activation also arose following long-term culture of ER-positive breast cancer lines in the presence of saracatinib. These data indicate the utility of proteomic analysis of drug-resistant tumors to identify potential means of drug resistance. The use of mTOR kinase inhibitors with saracatinib may subvert drug resistance and prove to be more effective than saracatinib alone.

KW - Breast cancer

KW - Cell cycle

KW - Fulvestrant

KW - p27

KW - Src inhibitor

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=79959249550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959249550&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1024-7

DO - 10.1007/s10549-010-1024-7

M3 - Article

VL - 128

SP - 69

EP - 78

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -